TFM
OVID icon

TFC Financial Management’s Ovid Therapeutics OVID Stock Holding History

TFC Financial Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69K Hold
1,000
– – ﹤0.01% 536
2026
Q1 		$2.22K Hold
1,000
– – ﹤0.01% 528
2025
Q4 		$1.63K Buy
+1,000
New +$1.54K ﹤0.01% 551

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TFC Financial Management's OVID Position: Q2 2026 in Review

TFC Financial Management held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 1,000 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

TFC Financial Management first reported a position in OVID in Q4 2025 and has held it in 3 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • TFC Financial Management held 1,000 shares of Ovid Therapeutics worth $2.69K as of Q2 2026.
  • TFC Financial Management left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #536 holding.
  • TFC Financial Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.